Aarti Drugs · NSE: AARTIDRUGS · BSE: 524348
Q3 FY25 results · Oct–Dec 2024
Aarti Drugs reported revenue from operations of ₹556.60 crore (down 8.1% from Q3 FY24) and net profit of ₹37.09 crore (up 1.0% from Q3 FY24) for Q3 FY25 (Oct–Dec 2024), on a consolidated basis.
| Item | Q3 FY25 | Q3 FY24 | YoY | Q2 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 556.60 | 605.94 | −8.1% | 598.33 | −7.0% |
| Other income | 11.90 | 1.67 | +612.6% | 1.48 | +704.1% |
| Total income | 568.50 | 607.61 | −6.4% | 599.81 | −5.2% |
| Profit before tax | 50.76 | 51.55 | −1.5% | 45.88 | +10.6% |
| Net profit for the period | 37.09 | 36.71 | +1.0% | 34.96 | +6.1% |
| Attributable to shareholders of the company | 37.05 | 36.67 | +1.0% | 35.01 | +5.8% |
| EPS, basic (₹) | 4.06 | 3.99 | +1.8% | 3.83 | +6.0% |
| Net margin (%) | 6.7 | 6.1 | 5.8 |
| Item | Q3 FY25 | Q3 FY24 | YoY | Q2 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 514.54 | 538.21 | −4.4% | 543.09 | −5.3% |
| Other income | 11.37 | 1.68 | +576.8% | 0.38 | 30x |
| Total income | 525.91 | 539.89 | −2.6% | 543.47 | −3.2% |
| Profit before tax | 52.03 | 42.87 | +21.4% | 40.89 | +27.2% |
| Net profit for the period | 38.53 | 31.62 | +21.9% | 30.39 | +26.8% |
| EPS, basic (₹) | 4.22 | 3.44 | +22.7% | 3.33 | +26.7% |
| Net margin (%) | 7.5 | 5.9 | 5.6 |
Consolidated
- Filed with BSE
- 30 Jan 2025, 14:06 IST
- Board meeting
- 29 Jan 2025
- Period
- 01 Oct 2024 to 31 Dec 2024
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 30 Jan 2025, 14:06 IST
- Board meeting
- 29 Jan 2025
- Period
- 01 Oct 2024 to 31 Dec 2024
- Review status
- Audited
- Source
- XBRL filing on BSE